Development of live attenuated influenza vaccines against pandemic influenza strains

Expert Review of Vaccines

Volumn 13, Issue 7, 2014, Pages 855-871

  Coelingh, Kathleen L ^a   Luke, Catherine J ^b   Jin, Hong ^c   Talaat, Kawsar R ^d  

^a Astra Zeneca One Med Immune Way   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c MedImmune Vaccines Inc   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

intranasal influenza vaccine; LAIV; pandemic influenza vaccine

Indexed keywords

CONTRACEPTIVE AGENT; IMMUNOGLOBULIN G ANTIBODY; INACTIVATED SUBVIRION VACCINE; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; NOSE SPRAY; OSELTAMIVIR; PLACEBO; UNCLASSIFIED DRUG; VIRUS VACCINE; LIVE VACCINE; VIRUS ANTIGEN;

2009 H1N1 INFLUENZA; ABNORMAL LABORATORY RESULT; ANTIBODY RESPONSE; ANTIVIRAL THERAPY; CHICKEN; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; GENETIC REASSORTMENT; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A; INFLUENZA VIRUS A H2N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H7N3; INFLUENZA VIRUS A H9N2; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; REVERSE GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEASONAL INFLUENZA; SEROCONVERSION; VACCINE PRODUCTION; VERO CELL LINE; VIRUS SHEDDING; VIRUS STRAIN; ANIMAL; BIRD; CLASSIFICATION; DISEASE OUTBREAKS; IMMUNOLOGY; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; PANDEMICS; TRANSMISSION;

ANIMALS; ANTIGENS, VIRAL; BIRDS; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; VACCINES, ATTENUATED;

EID: 84902332892     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.922417     Document Type: Review

References (51)

1. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;360(25):2605-15
2. Friede M, Palkonyay L, Alfonso C, et al. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Vaccine 2011; 29(Suppl 1):A2-7
3. Karron RA, Callahan K, Luke C, et al. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Dis 2009;199(5):711-16.
4. Talaat KR, Karron RA, Callahan KA, et al. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a phase I trial in healthy adults. Vaccine 2009;27(28):3744-53.
5. Karron RA, Talaat K, Luke C, et al. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 2009;27(36): 4953-60.
6. Talaat KR, Karron RA, Luke CJ, et al. An open label phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults. Vaccine 2011;29(17):3144-8.
7. Talaat KR, Karron RA, Liang PH, et al. An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults. Influenza Other Respir Viruses 2013; 7(1):66-73.
8. Quadrivalent influenza vaccine live, intranasal full prescribing information. MedImmune; Gaithersburg, MD, USA: 2013
9. Ambrose CS, Yi T, Falloon J. An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years. Influenza Other Respir Viruses 2011;5(6):389-97
10. Ambrose CS, Luke C, Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respir Viruses 2008;2(6):183-92
11. Baxter R, Toback SL, Sifakis F, et al. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18-49 years of age. Vaccine 2012;30(20):3053-60
12. Baxter R, Toback SL, Sifakis F, et al. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age. Vaccine 2012;30(19):2989-98
13. Toback SL, Ambrose CS, Eaton A, et al. A postlicensure evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 24-59 months of age. Vaccine 2013;31(14):1812-18
14. Ambrose CS, Wu X, Knuf M, Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. Vaccine 2012;30(5):886-92
15. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999;282(2):137-44 (Pubitemid 29323803)
16. Ambrose CS, Wu X, Jones T, Mallory RM. The role of nasal IgA in children vaccinated with live attenuated influenza vaccine. Vaccine 2012;30(48):6794-801
17. Forrest BD, Pride MW, Dunning AJ, et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008;15(7):1042-53 (Pubitemid 352018317)
18. Coelingh K, Wu X, Mallory R, Ambrose CS. Serum HAI antibody response to LAIV in 2-to 49-year-olds. Pediatric Academic Societies Annual Meeting; 4-7 June 2013;Washington, DC, USA
19. Bandell A, Woo J, Coelingh K. Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference. Expert Rev Vaccines 2011;10(8):1131-41
20. He XS, Holmes TH, Zhang C, et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006; 80(23):11756-66 (Pubitemid 44788888)
21. Hoft DF, Babusis E, Worku S, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 2011;204(6): 845-53
22. Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune responses to influenza virus infection. Virus Res 2011;162(1-2):19-30
23. Block SL, Toback SL, Yi T, Ambrose CS. Efficacy of a single dose of live attenuated influenza vaccine in previously unvaccinated children: a subgroup analysis of children 2 to 6 years of age. Clin Ther 2009;31(10): 2140-7
24. Piedra PA, Gaglani MJ, Kozinetz CA, et al. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics 2007;120(3):e553-64 (Pubitemid 47358268)
25. Jin H, Lu B, Zhou H, et al. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 2003;306(1): 18-24 (Pubitemid 36293391)
26. Suguitan AL Jr, McAuliffe J, Mills KL, et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 2006;3(9):e360
27. Min JY, Vogel L, Matsuoka Y, et al. A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys. J Virol 2010;84(22): 11950-60
28. Jin H, Chen Z, Liu J, Kemble G. Genetic engineering of live attenuated influenza viruses. Methods Mol Biol 2012;865:163-74
29. Chen Z, Wang W, Zhou H, et al. Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J Virol 2010;84(1):44-51
30. Peiris JS, Yu WC, Leung CW, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004; 363(9409):617-19 (Pubitemid 38264181)
31. Li KS, Guan Y, Wang J, et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004;430(6996):209-13 (Pubitemid 38902429)
32. Guan Y, Poon LL, Cheung CY, et al. H5N1 influenza: a protean pandemic threat. Proc Natl Acad Sci USA 2004;101(21): 8156-61 (Pubitemid 38698070)
33. Chen H, Matsuoka Y, Swayne D, et al. Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine 2003;21(27-30): 4430-6 (Pubitemid 37138704)
34. Joseph T, McAuliffe J, Lu B, et al. Evaluation of replication and pathogenicity of avian influenza a H7 subtype viruses in a mouse model. J Virol 2007;81(19): 10558-66 (Pubitemid 47463329)
35. Gillim-Ross L, Santos C, Chen Z, et al. Avian influenza H6 viruses productively infect and cause illness in mice and ferrets. J Virol 2008;82(21):10854-63 (Pubitemid 352691160)
36. Jin H, Manetz S, Leininger J, et al. Toxicological evaluation of live attenuated, cold-adapted H5N1 vaccines in ferrets. Vaccine 2007;25(52):8664-72 (Pubitemid 350192061)
37. Rudenko LG, Slepushkin AN, Monto AS, et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis 1993;168(4):881-7 (Pubitemid 23282559)
38. Murphy BR, Tierney EL, Barbour BA, et al. Use of the enzyme-linked immunosorbent assay to detect serum antibody responses of volunteers who received attenuated influenza A virus vaccines. Infect Immun 1980;29(2): 342-7 (Pubitemid 10040140)
39. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999;37(4):937-43 (Pubitemid 29140593)
40. Clements ML, O'Donnell S, Levine MM, et al. Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect Immun 1983;40(3): 1044-51 (Pubitemid 13103155)
41. Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001; 19(13-14):1732-7 (Pubitemid 32175735)
42. Stephenson I, Nicholson KG, Colegate A, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003;21(15): 1687-93 (Pubitemid 36287599)
43. Goji NA, Nolan C, Hill H, et al. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 2008;198(5):635-41
44. Gurwith M, Lock M, Taylor EM, et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 2013; 13(3):238-50
45. Ledgerwood JE, Wei CJ, Hu Z, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011;11(12):916-24
46. Ledgerwood JE, Zephir K, Hu Z, et al. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the h5 DNA influenza vaccine priming effect. J Infect Dis 2013;208(3):418-22
47. Talaat KR, Luke CJ, Khurana S, et al. A live attenuated H5N1 vaccine induces long-term immunity in the absence of a primary antibody response. J Infect Dis 2014. [Epub ahead of print].
48. Mallory RM, Malkin E, Ambrose CS, et al. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS One 2010;5(10): e13755
49. Griffin MR, Monto AS, Belongia EA, et al. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS One 2011;6(8):e23085
50. Uzicanin A, Thompson M, Smith P, et al. Effectiveness of 1 dose of influenza A (H1N1) 2009 monovalent vaccines in preventing reverse-transcription polymerase chain reaction-confirmed H1N1 infection among school-aged children in Maine. J Infect Dis 2012;206(7):1059-68
51. Chen Z, Santos C, Aspelund A, et al. Evaluation of live attenuated influenza A virus H6 vaccines in mice and ferrets. J Virol 2009;83(1):65-72